Ai Li

发表

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Troy Guthrie, Kevin Harrington, Lee Cranmer, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

P. Philip, A. Zhu, M. Borad, 2021, The lancet. Gastroenterology & hepatology.

Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.

M. Galsky, D. Bajorin, J. Rosenberg, 2020, European urology.

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.

I. Puzanov, M. Milhem, H. Kaufman, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.

H. Wildiers, J. Jassem, L. Dirix, 2015, Breast.

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma

M. Galsky, D. Bajorin, J. Rosenberg, 2021, Clinical genitourinary cancer.

Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.

P. Philip, G. Abou-Alfa, R. Kelley, 2021 .

Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.

I. Puzanov, M. Milhem, H. Kaufman, 2015 .

Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.

I. Puzanov, M. Milhem, H. Kaufman, 2014 .

Increased systemic immune-inflammation index independently predicts poor survival for hormone receptor-negative, HER2-positive breast cancer patients

Jinming Yu, Yi Sun, J. Yue, 2019, Cancer management and research.

Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.

S. Roychowdhury, A. Lamarca, I. Borbath, 2020, Future oncology.

Phase 2, multicenter, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for resectable stage IIIB/C and IVM1a melanoma (MEL).

M. Ross, M. Chastain, R. Andtbacka, 2015 .

Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)

K. Harrington, N. Senzer, K. Delman, 2014, Journal of Immunotherapy for Cancer.

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

G. Linette, M. Ross, K. Harrington, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.